SEMA3A and osteosarcoma: In the present study, we report that human recombinant (exogenous) and osteosarcoma-derived Sema3A reduced the ability of osteosarcoma cells to enhance osteoclastogenesis in vitro and in vivo but it exerted differential effects on osteosarcoma associated osteoblast changes and ectopic bone formation in vivo.